journal
MENU ▼
Read by QxMD icon Read
search

Clinical Breast Cancer

journal
https://www.readbyqxmd.com/read/28529029/metaplastic-carcinoma-of-the-breast-is-more-aggressive-than-triple-negative-breast-cancer-a%C3%A2-study-from-a-single-institution-and-review-of%C3%A2-literature
#1
Dima El Zein, Melissa Hughes, Shicha Kumar, Xuan Peng, Tolutope Oyasiji, Hossam Jabbour, Thaer Khoury
BACKGROUND: We aimed to describe our experience with metaplastic breast carcinoma (MBC), evaluate its clinical outcome compared with triple-negative breast cancer (TNBC), and provide a through and comprehensive review of the literature to date. MATERIALS AND METHODS: We reviewed MBC cases (n = 46) from our institution. The following variables were recorded: tumor histologic subtype, Nottingham grade, tumor size, lymph node status, Tumor, Node, Metastases stage, biomarkers profile, patient's age and race, therapy modality (chemotherapy and radiation), and survival (disease-free survival [DFS] and overall survival [OS])...
April 26, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28501502/urtica-dioica-extract-inhibits-proliferation-and-induces-apoptosis-and-related-gene-expression-of-breast-cancer-cells-in%C3%A2-vitro-and-in%C3%A2-vivo
#2
Ali Mohammadi, Behzad Mansoori, Pooneh Chokhachi Baradaran, Vahid Khaze, Mahyar Aghapour, Mehrdad Farhadi, Behzad Baradaran
INTRODUCTION: Currently, because the prevalence of breast cancer and its consequent mortality has increased enormously in the female population, a number of studies have been designed to identify natural products with special antitumor properties. The main purpose of the present study was to determine the effect of Urtica dioica on triggering apoptosis and diminishing growth, size, and weight of the tumor in an allograft model of BALB/c mice. MATERIALS AND METHODS: In the present study, a BALB/c mouse model of breast cancer (4T1) was used...
April 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28487053/a-novel-less-invasive-approach-for-axillary-staging-after-neoadjuvant-chemotherapy-in-patients-with-axillary-node-positive-breast-cancer-by-combining-radioactive-iodine-seed-localization-in-the-axilla-with-the-sentinel-node-procedure-risas-a-dutch-prospective
#3
Thiemo J A van Nijnatten, Janine M Simons, Marjolein L Smidt, Carmen C van der Pol, Paul J van Diest, Agnes Jager, David van Klaveren, Boen L R Kam, Marc B I Lobbes, Maaike de Boer, Kees Verhoef, Linetta B Koppert, Ernest J T Luiten
BACKGROUND: In 1 of 3 patients with initial lymph node-positive (cN(+)) breast cancer, neoadjuvant chemotherapy (NAC) results in an axillary pathologic complete response (ax-pCR). This urges the need for a less-invasive axillary staging method. Recently introduced less-invasive procedures have been insufficient in accurately identifying ax-pCR. Therefore, we propose a novel less-invasive axillary staging procedure: the Radioactive Iodine Seed localization in the Axilla with the Sentinel node procedure (RISAS), a combination of the procedure of marking axillary lymph nodes with radioactive iodine seeds (MARI) and sentinel lymph node biopsy (SLNB)...
April 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28495572/a-tumor-ultrasound-guided-incision-tugi-approach-to-nipple-sparing-mastectomy-balancing-oncologic-safety-and-technical%C3%A2-outcomes
#4
Emil J Fernando, Benjamin R Eskenazi, Risal S Djohan, Stephen R Grobmyer
BACKGROUND: Nipple-sparing mastectomy (NSM) is a prevalent operation for patients with breast cancer. Indications have been limited to tumors accessible via radial, infra-mammary, or periareolar incisions out of concern for oncologic and technical safety. We study an alternative approach to NSM based on tumor ultrasound-guided incisions (TUGI) and report its oncologic and technical outcomes. MATERIALS AND METHODS: A retrospective chart review examined patients who underwent TUGI NSM between 2013 and 2016...
April 12, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28479052/patterns-of-care-and-clinical-outcomes-of-her2-positive-metastatic-breast-cancer-patients%C3%A2-with-newly-diagnosed-stage-iv-or-recurrent-disease-undergoing-first-line-trastuzumab-based-therapy-a-multicenter-retrospective-cohort-study
#5
Matteo Lambertini, Arlindo R Ferreira, Antonio Di Meglio, Francesca Poggio, Fabio Puglisi, Federico Sottotetti, Filippo Montemurro, Elena Poletto, Antonio Bernardo, Emanuela Risi, Chiara Dellepiane, Valentina Sini, Gabriele Minuti, Donatella Grasso, Sara Fancelli, Lucia Del Mastro
BACKGROUND: The aim of the study was to compare the patterns of care and clinical outcomes of HER2-positive metastatic breast cancer (MBC) patients with de novo or recurrent disease who underwent first-line trastuzumab-based therapy. PATIENTS AND METHODS: This was a multicenter retrospective cohort study including consecutive patients with HER2-positive MBC who received first-line trastuzumab-based therapy. Analyses on treatment response and effectiveness were conducted according to type of metastatic presentation (ie, de novo vs...
April 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28456487/interval-breast-cancer-versus-screen-detected-cancer-comparison-of-clinicopathologic-characteristics-in-a-single-center-analysis
#6
Gabriele Bellio, Riccardo Marion, Fabiola Giudici, Sara Kus, Maura Tonutti, Fabrizio Zanconati, Marina Bortul
BACKGROUND: The introduction of breast screening programs has raised the problem of interval breast cancers (IBC). The aims of this study were to analyze the impact of IBC on the screening program, to compare IBC and screen-detected cancers (SDC), and to identify possible predictors of mortality. PATIENTS AND METHODS: Patients with breast cancer diagnosed during the regional breast screening program between January 2008 and December 2013 at a single center in Italy were included...
April 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28456486/sodium-salicylate-inhibits-urokinase-activity-in-mda-mb-231-breast-cancer-cells
#7
Josip Madunić, Luka Horvat, Ivana Majstorović, Iga Jodłowska, Mariastefania Antica, Maja Matulić
INTRODUCTION: Sodium salicylate (NaS) is a derivate of acetylsalicylic acid or aspirin, used as a nonsteroidal anti-inflammatory drug for centuries, for its analgesic and anti-inflammatory effects. It was found to modulate different signaling pathways, in a cell-specific way. Here, we explore the effect of NaS on cell growth and urokinase activity in MDA MB-231 breast cancer cells. MATERIALS AND METHODS: We analyzed the effect of NaS treatment on cell growth by flow cytometry and viability test...
April 6, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28454926/predictive-factors-for-nonsentinel-lymph-node-metastasis-in-patients-with-positive-sentinel-lymph-nodes-after-neoadjuvant-chemotherapy-nomogram-for-predicting-nonsentinel-lymph-node-metastasis
#8
Jai Min Ryu, Se Kyung Lee, Ji Young Kim, Jonghan Yu, Seok Won Kim, Jeong Eon Lee, Se Hwan Han, Yong Sik Jung, Seok Jin Nam
INTRODUCTION: Axillary lymph node (ALN) status is an important prognostic factor for breast cancer patients. With increasing numbers of patients undergoing neoadjuvant chemotherapy (NAC), issues concerning sentinel lymph node biopsy (SLNB) after NAC have emerged. PATIENTS AND METHODS: We analyzed the clinicopathologic features and developed a nomogram to predict the possibility of nonsentinel lymph node (NSLN) metastases in patients with positive SLNs after NAC...
April 6, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28438672/the-management-strategy-of-benign-solitary-intraductal-papilloma-on-breast-core-biopsy
#9
Dayoung Ko, Eunyoung Kang, So Yeon Park, Sun Mi Kim, Mijung Jang, Bo La Yun, Sumin Chae, Yerang Jang, Hye Jin Kim, Sung-Won Kim, Eun-Kyu Kim
BACKGROUND: Intraductal papilloma (IDP) is well-known as one of the common benign breast lesions requiring excision. However, treatment of IDP without atypia is controversial. The aim of our study was to determine the proper management of solitary IDP by core needle biopsy (CNB). PATIENTS AND METHODS: We retrospectively reviewed patients with solitary IDP confirmed by CNB from March 2003 to March 2015. We collected data about final pathology after excision, as well as clinical, histologic, and radiologic findings at initial diagnosis...
April 1, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28433540/er-%C3%AE-36-interactions-with-cytosolic-molecular-network-in-acquired-tamoxifen-resistance
#10
REVIEW
Azin Teymourzadeh, Sepideh Mansouri, Leila Farahmand, Aysooda Hosseinzade, Keivan Majidzadeh-A
According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced mostly in a way to target this receptor. Anti-estrogen therapies mostly target Estrogen receptor and block its underlying signaling pathways. Nevertheless, resistance to these agents made the condition more complicated...
March 30, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28433541/the-impact-of-2013-updated-asco-cap-her2-guidelines-on-the-diagnosis-and-management-of-invasive-breast-cancer-a-single-center-study-of-1739-cases
#11
Xiaofei Zhang, Ira Bleiweiss, Shabnam Jaffer, Anupma Nayak
BACKGROUND: The purpose of this study was to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists. MATERIALS AND METHODS: Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014). RESULTS: Using 2013 guidelines, 255 (15%; 95% confidence interval [CI], 13%-16%) cases were classified as HER2(+) as opposed to 186 (11%; 95% CI, 9%-12%) by 2007 guidelines (odds ratio [OR] 1...
March 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28412326/no-acute-changes-in-lvef-observed-with-concurrent-trastuzumab-and-breast-radiation-with-low-heart-doses
#12
Shelly X Bian, Mariam P Korah, Taylor R Whitaker, Lingyun Ji, Susan Groshen, Eugene Chung
INTRODUCTION/BACKGROUND: Treatment for HER2-postitive breast cancer often includes trastuzumab, breast/chest wall (CW) radiation (RT), and anthracyclines, all of which have cardiac toxicity. We aimed to evaluate the relationship between heart dose and acute left ventricular ejection fraction (LVEF) changes in patients who received concurrent trastuzumab and breast/CW RT with and without anthracycline use. PATIENTS AND METHODS: We retrospectively reviewed all nonmetastatic breast cancer patients from 2008 to 2015 who received concurrent trastuzumab and breast/CW RT...
March 23, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28416193/lep-rs7799039-lepr-rs1137101-and-adipoq-rs2241766-and-1501299-polymorphisms-are-associated-with-obesity-and-chemotherapy-response-in-mexican-women-with-breast-cancer
#13
Alejandra Méndez-Hernández, Martha Patricia Gallegos-Arreola, Hortensia Moreno-Macías, Jorge Espinosa Fematt, Rebeca Pérez-Morales
BACKGROUND: Obesity plays a major role in the pathogenesis of breast cancer. Leptin (LEP) and adiponectin (ADIPOQ) are important in the regulation of adipose tissue. The response to cancer treatment depends on the histological and molecular tumor type, clinical stage, and genetic variability that might promote carcinogenic development. The aim of this study was to investigate the association between overweight/obesity and polymorphisms in the LEP (rs7799039), LEP receptor (LEPR; rs1137101), and ADIPOQ genes (rs2241766, rs1501299) with the response to breast cancer treatment in Mexican women...
March 22, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28420584/neuroendocrine-carcinoma-of-the-breast-with-endobronchial-metastases-and-syndrome-of-inappropriate-antidiuretic-hormone-secretion
#14
Anaum Maqsood, Thaer Khoury, Prasanna Kumar, Antonios Papanicolau-Sengos, Amy P Early
No abstract text is available yet for this article.
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28410844/folate-receptor-alpha-expression-is-associated-with-increased-risk-of-recurrence-in-triple-negative-breast-cancer
#15
Paula S Ginter, Patrick J McIntire, Xiaoyan Cui, Lina Irshaid, Yifang Liu, Zhengming Chen, Sandra J Shin
BACKGROUND: Folate receptor alpha (FOLR1) has been identified as a potential prognostic and therapeutic target in breast cancer. The limited studies evaluating the role of FOLR1 in breast cancer have shown that FOLR1 protein expression is enriched in triple-negative breast cancer (TNBC) and associated with poor prognosis in all breast cancer types. Newly developed anti-FOLR1 therapy could potentially be used in patients with TNBC for whom few therapeutic options exist. We sought to evaluate FOLR1 protein expression in a cohort of patients with TNBC to determine its prevalence and prognostic value...
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28396099/management-of-isolated-locoregional-recurrences%C3%A2-in-breast-cancer-a-review-of-local%C3%A2-and-systemic-modalities
#16
REVIEW
Tabassum Wadasadawala, Rohit Vadgaonkar, Jyoti Bajpai
Locoregional recurrence (LRR) after adequate treatment of primary breast cancer poses a therapeutic challenge. Advances in the management of breast cancer have led to significant improvements in survival. With this advantage, it is observed that the incidence of LRR has relatively decreased. Systemic involvement should be ruled out in patients presenting with locoregionally recurrent disease, as isolated LRR requires a treatment with curative intent. Salvage mastectomy following ipsilateral breast tumor recurrence is a time-tested treatment option and widely accepted...
March 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28385537/phase-i-trial-of-everolimus-and-capecitabine-in-metastatic-her2-breast-cancer
#17
Gregory A Vidal, Mary Chen, Shruti Sheth, Tiffany Svahn, Ellie Guardino
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is a driver of breast tumorigenesis. The mTOR inhibitor everolimus reverses antihormonal therapy resistance and is an approved therapy for metastatic breast cancer. A synergistic effect with fluoropyrimidine has been suggested. The present study evaluated the safety and tolerability of an all-oral combination of everolimus and capecitabine for metastatic breast cancer (MBC). PATIENTS AND METHODS: MBC patients naive to capecitabine and mTOR inhibitors who had received ≤ 3 previous chemotherapy regimens in the metastatic setting were eligible for the present study...
March 16, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28365336/associations-between-patient-and-anthropometric-characteristics-and-aromatase-inhibitor-discontinuation
#18
N Lynn Henry, Kelly Speth, Anneleen Lintermans, Kelley M Kidwell, Rachel Carlson, Daniel F Hayes, Patrick Neven
BACKGROUND: Toxicity can lead to noncontinuation of adjuvant endocrine therapy. We hypothesized that endocrine therapy-induced changes in grip strength would predict for early discontinuation of therapy because of musculoskeletal toxicity and would be associated with a patient's body mass index. PATIENTS AND METHODS: Postmenopausal women with breast cancer starting a new adjuvant endocrine therapy were enrolled in the present study. The patients were monitored for 12 months to assess their symptoms, endocrine therapy adherence and change in grip strength and baseline body mass index...
March 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28366406/nab-paclitaxel-in-advanced-her2-negative-breast-cancer-patients-efficacy-and-safety-beyond-clinical-trials
#19
Antonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, Elena Rota Caremoli, Anna Rita Gambaro, Antonella Ferzi, Francesca Riva, Donatella Grasso, Marco Danova, Emiliana Tarenzi, Valter Torri, Marina E Cazzaniga
BACKGROUND: Few data are available regarding efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel in advanced breast cancer patients outside a controlled trial, especially for the weekly schedule. PATIENTS AND METHODS: We prospectively collected data of advanced breast cancer patients who were candidates to be treated with weekly (125 mg/m(2) for 3 consecutive weeks followed by a 1-week rest) or every 3 weeks (260 mg/m(2)) schedules of nab-paclitaxel, according to physician's decision...
March 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28359730/the-changing-role-of-vacuum-assisted-biopsy-of-the-breast-a-new-prototype-of-minimally-invasive-breast-surgery
#20
Ian C Bennett
No abstract text is available yet for this article.
March 9, 2017: Clinical Breast Cancer
journal
journal
34827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"